Markets:

Overview

News

Currencies

International

Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

440.83 -4.00 (-0.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

2 Under-the-Radar Stocks to Buy and Hold ↗

March 10, 2026

These biotechs are slowly making a name for themselves.

Via The Motley Fool

Madrigal (MDGL) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Madrigal (MDGL) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Intellectual Property

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

Via The Motley Fool

Topics Regulatory Compliance

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Reports Q4 2025 Revenue Beat and Significant EPS Miss ↗

February 19, 2026

Via Chartmill

Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo ↗

February 11, 2026

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Via The Motley Fool

Topics Regulatory Compliance

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

Why Madrigal Pharmaceuticals Stock Slumped on Tuesday ↗

January 06, 2026

The stock has had quite the run following Rezdiffra's 2024 approval by the FDA.

Via The Motley Fool

Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗

January 05, 2026

There is a key difference between these two biotechs.

Via The Motley Fool

Topics Bankruptcy

2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗

January 03, 2026

The pharmaceutical leader looks poised to stop the bleeding.

Via The Motley Fool

2 Predictions for Novo Nordisk in 2026 ↗

December 14, 2025

The company's worst days might be behind it.

Via The Motley Fool

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗

December 09, 2025

They haven't peaked yet.

Via The Motley Fool

Topics Intellectual Property

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum ↗

November 24, 2025

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.

Via Stocktwits

Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 20, 2025

Via Benzinga

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗

November 09, 2025

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

Via Benzinga

Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings: Revenue Beat and EPS Miss Drive Pre-Market Surge ↗

November 04, 2025

Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake.

Via Chartmill

A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast ↗

November 03, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock ↗

October 15, 2025

Via Benzinga

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Via Benzinga

A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts ↗

September 29, 2025

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.

Via Benzinga

MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template ↗

September 24, 2025

Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions